Bimatoprost 0.01% Vs Bimatoprost 0.03%: a 12-month Prospective Trial of Clinical and in Vivo Confocal Microscopy in Glaucoma Patients

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2014 Jan 18

PMID 24434659

Citations 17

Authors

M Figus

M Nardi

P Piaggi

M Sartini

G Guidi

L Martini

S Lazzeri

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the safety of two commercially available formulations of bimatoprost eye drops: 0.03 and 0.01% ophthalmic solutions.

Methods: This was a randomized, prospective, parallel-group, open-label, cohort study. A total of 60 glaucoma patients (60 eyes) under bimatoprost 0.03% monotherapy since at least 1 year were enrolled. Selected patients were randomized to receive a single drop of bimatoprost 0.01% (n=30) or bimatoprost 0.03% (n=30) ophthalmic solutions for 12 months. Statistical analysis was performed using paired t-test and repeated measures ANOVA test.

Results: Global clinical score (the sum of pruritus, stinging/burning, blurred vision, sticky eye sensation, eye dryness sensation, and foreign body sensation) significantly decreased in the bimatoprost 0.01% group from baseline 4.7 ± 3.8 to 2.9 ± 2.3 (P < 0.001) and 2.5 ± 2.0 (P < 0.001) at 6-month and 12-month follow-ups, respectively. Comparison between groups showed differences at both follow-up visits (P = 0.003 and P < 0.001, respectively). In vivo confocal microscopy revealed a significant increase in goblet cell density in the bimatoprost 0.01% group compared with the bimatoprost 0.03% group (P<0.001 at both follow-up visits). All functional parameters and conjunctival hyperemia improved in the bimatoprost 0.01% group at each follow-up visit (P < 0.05) and in comparison with bimatoprost 0.03% (P < 0.05).

Conclusion: The results of this trial suggest that bimatoprost 0.01% eye drops seem to decrease the ocular discomfort with respect to bimatoprost 0.03% eye drops.

Citing Articles

From Eye Care to Hair Growth: Bimatoprost.

Zeppieri M, Gagliano C, Spadea L, Salati C, Chukwuyem E, Enaholo E Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794131 PMC: 11124470. DOI: 10.3390/ph17050561.

Preservative-Free Bimatoprost 0.01% Ophthalmic Gel for Glaucoma Therapy: A Phase III Randomized Controlled Trial.

Munoz-Negrete F, Topouzis F, Oddone F, Nissle S, Rokicki D, Januleviciene I J Glaucoma. 2024; 33(6):422-430.

PMID: 38506750 PMC: 11146180. DOI: 10.1097/IJG.0000000000002371.

Comparison of Transcriptomic Analysis of the Conjunctiva in Glaucoma-Treated Eyes with Dry Eyes and Healthy Controls.

Carnero E, Irigoyen-Banegil C, Gutierrez I, Extramiana L, Sabater A, Moreno-Montanes J Biomolecules. 2024; 14(1).

PMID: 38254630 PMC: 10813521. DOI: 10.3390/biom14010030.

Outcome of combined trabeculectomy with cataract surgery in patients on prostaglandin analogs and aqueous suppressants.

Aswin P, Mohan N, Sundar B, Ponnat A, Radhakrishnan S, Krishnadas S Indian J Ophthalmol. 2024; 72(3):439-446.

PMID: 38189457 PMC: 11001227. DOI: 10.4103/IJO.IJO_2317_23.

Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study.

Petricca S, Celenza G, Costagliola C, Tranfa F, Iorio R Int J Mol Sci. 2022; 23(22).

PMID: 36430590 PMC: 9695990. DOI: 10.3390/ijms232214113.

References

Katz L, Cohen J, Batoosingh A, Felix C, Shu V, Schiffman R . Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010; 149(4):661-671.e1. DOI: 10.1016/j.ajo.2009.12.003. View

Cantor L, Hoop J, Morgan L, Wudunn D, Catoira Y . Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006; 90(11):1370-3. PMC: 1857505. DOI: 10.1136/bjo.2006.094326. View

Nakamura T, Yamada M, Teshima M, Nakashima M, To H, Ichikawa N . Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull. 2007; 30(12):2360-4. DOI: 10.1248/bpb.30.2360. View

Prabhasawat P, Tseng S . Impression cytology study of epithelial phenotype of ocular surface reconstructed by preserved human amniotic membrane. Arch Ophthalmol. 1997; 115(11):1360-7. DOI: 10.1001/archopht.1997.01100160530001. View

Whitson J, Cavanagh H, Lakshman N, Petroll W . Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006; 23(5):663-71. DOI: 10.1007/BF02850305. View

van der Valk R, Webers C, Schouten J, Zeegers M, Hendrikse F, Prins M . Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112(7):1177-85. DOI: 10.1016/j.ophtha.2005.01.042. View

Pajoohesh-Ganji A, Pal-Ghosh S, Tadvalkar G, Stepp M . Corneal goblet cells and their niche: implications for corneal stem cell deficiency. Stem Cells. 2012; 30(9):2032-43. PMC: 3635098. DOI: 10.1002/stem.1176. View

Goldberg I, Li X, Selaru P, Paggiarino D . A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2008; 18(3):408-16. DOI: 10.1177/112067210801800315. View

Tung J, Tafreshi A, Weinreb R, Slight J, Medeiros F, Liu J . Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure. BMJ Open. 2012; 2(4). PMC: 3951976. DOI: 10.1136/bmjopen-2012-001106. View

10.

Quigley H . Glaucoma. Lancet. 2011; 377(9774):1367-77. DOI: 10.1016/S0140-6736(10)61423-7. View

11.

Taylor H . The biological effects of UV-B on the eye. Photochem Photobiol. 1989; 50(4):489-92. DOI: 10.1111/j.1751-1097.1989.tb05553.x. View

12.

Nelson J . Impression cytology. Cornea. 1988; 7(1):71-81. View

13.

Chauhan B, Mikelberg F, Balaszi A, LeBlanc R, Lesk M, Trope G . Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008; 126(8):1030-6. DOI: 10.1001/archopht.126.8.1030. View

14.

Astin M, Stjernschantz J, Selen G . Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994; 59(4):401-7. DOI: 10.1006/exer.1994.1124. View

15.

Maier P, Funk J, Schwarzer G, Antes G, Falck-Ytter Y . Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005; 331(7509):134. PMC: 558697. DOI: 10.1136/bmj.38506.594977.E0. View

16.

Hamacher T, Airaksinen J, Saarela V, Liinamaa M, Richter U, Ropo A . Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf ). 2008; 242:14-9. DOI: 10.1111/j.1755-3768.2008.01381.x. View

17.

Bean G, Camras C . Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008; 53 Suppl1:S69-84. DOI: 10.1016/j.survophthal.2008.08.012. View

18.

Hollo G . The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2006; 6(1):45-52. DOI: 10.1517/14740338.6.1.45. View

19.

Tiffany J . Tears in health and disease. Eye (Lond). 2003; 17(8):923-6. DOI: 10.1038/sj.eye.6700566. View

20.

Sharif N, Williams G, Kelly C . Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 2001; 432(2-3):211-3. DOI: 10.1016/s0014-2999(01)01486-8. View